Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2025 05:52 ET | Source: Vantage Biosciences

Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

Vantage Biosciences, a clinical-stage biotechnology company advancing innovative therapies for diabetic eye diseases, announces first NPDR patient dosed.